Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SKYE Relative to the S&P 500

SKYE Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Skye Bioscience Inc. (OTCMKT:SKYE) seasonal charts above shows that a Buy Date of March 10 and a Sell Date of June 8 has resulted in a geometric average return of 11.64% above the benchmark rate of the S&P 500 Total Return Index over the past 8 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 8 years by an average of 111.64% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 8 years of data is available for shares of SKYE, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company’s lead compound, SBI-100, is initially being developed to treat ocular disease.

To download SKYE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SKYE